Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX versus platinum-etoposide first-line therapy in metastatic poorly differentiated grade 3 gastroenteropancreatic or unknown-primary neuroendocrine carcinoma
2019-001013-16Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, irinotecan, oxaliplatin, cisplatin and etoposide in neuroendocrine carcinoma (NEC) and mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Progression-free survival by investigator assessment. Started May 2020; status: active.
02
Drugs
fluorouracilirinotecanoxaliplatincisplatinetoposide
03
Conditions
neuroendocrine carcinoma (NEC)mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)
Beyond the preview
Go deeper on 2019-001013-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001013-16.